Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TRFK-5 is a rat-derived IgG1 monoclonal antibody that specifically targets and neutralizes interleukin-5 (IL-5). IL-5 is a key cytokine responsible for the maturation, differentiation, and recruitment of eosinophils, which are central to the pathophysiology of allergic asthma and other eosinophilic inflammatory conditions. By binding to IL-5, TRFK-5 prevents the cytokine from interacting with its receptor on eosinophil precursors and mature cells, thereby inhibiting pulmonary eosinophilia and reducing airway hyperreactivity. Developed and utilized extensively in preclinical research by Schering-Plough and academic institutions, TRFK-5 has served as a critical tool in murine and non-human primate models to validate IL-5 as a therapeutic target for respiratory diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TRFK-5.